# A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)

> **NCT00383162** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 173 (actual)

## Conditions studied

- Migraine Disorders

## Interventions

- **DRUG:** Combination Product (sumatriptan succinate / naproxen sodium)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00383162
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 173 (ACTUAL)
- **Last updated:** 2017-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00383162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00383162, "A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00383162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*